Literature DB >> 28800049

Survival outcomes following aggressive treatment of oligometastatic breast cancer: a systematic review protocol.

Robyn Coombe1, Karolina Lisy, Jared Campbell, Gajen Perry, Subhita Prasannan.   

Abstract

REVIEW QUESTION/
OBJECTIVE: The objective of this systematic review is to assess the effectiveness of aggressive treatment of oligometastatic breast cancer (OMBC) on survival outcomes by conducting a meta-analysis of current available evidence.More specifically, the objectives are to identify the effectiveness of intensified multidisciplinary treatment with aggressive locoregional therapies on survival time, five-year survival rates and disease free survival. The population is adult women (18 years and over) with OMBC defined as single or few (five or less) metastases limited to a single organ and the comparative group is conventional palliative treatment aimed at disease control. Secondary objectives to be assessed will be adverse outcomes associated with intensified treatment regimes.

Entities:  

Mesh:

Year:  2017        PMID: 28800049     DOI: 10.11124/JBISRIR-2016-002954

Source DB:  PubMed          Journal:  JBI Database System Rev Implement Rep        ISSN: 2202-4433


  3 in total

1.  Successful treatment with proton beam therapy for a solitary sternal metastasis of breast cancer: a case report.

Authors:  Yojiro Ishikawa; Motohisa Suzuki; Hisashi Yamaguchi; Ichiro Seto; Masanori Machida; Yoshiaki Takagawa; Keiichi Jingu; Yasuyuki Kikuchi; Masao Murakami
Journal:  J Med Case Rep       Date:  2022-03-20

2.  A Case of Brachial Lymph Node Recurrences after the Resection of Locally Advanced Breast Cancer.

Authors:  Kayono Onishi; Rurina Watanuki; Takamichi Yokoe; Tsuguo Iwatani; Chisako Yamauchi; Tatsuya Onishi
Journal:  Case Rep Oncol       Date:  2022-08-30

3.  Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study.

Authors:  Yuxin Xie; Ji Ma; Xueming Xia; Hong Zheng; Qiheng Gou
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.